As of now, Amvuttra (vutrisiran) is FDA-approved specifically for polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis in adults — not wild-type ATTR amyloidosis.
Wild-type ATTR amyloidosis primarily affects the heart rather than the nerves, so polyneuropathy is less of a focus in that form of the condition. For Show Full Answer
As of now, Amvuttra (vutrisiran) is FDA-approved specifically for polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis in adults — not wild-type ATTR amyloidosis.
Wild-type ATTR amyloidosis primarily affects the heart rather than the nerves, so polyneuropathy is less of a focus in that form of the condition. For wild-type ATTR, the currently used treatments are focused on stabilizing the transthyretin protein to protect the heart. These include:
- Acoramidis
- Tafamidis
- Tafamidis meglumine
- Vutrisiran (Amvuttra)
It's worth noting that vutrisiran is being explored for wild-type ATTR in the context of heart involvement, and is listed among treatments being studied or used for that form. However, its role in wild-type ATTR polyneuropathy specifically is not well established.
The best step is to speak with an amyloidosis specialist who can assess whether any current or clinical trial options might be appropriate for your specific situation.
July 6
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
